

This material is an English translation of the press release announced on September 28, 2018 in Japanese, and the Japanese release is given priority about the content and the interpretation.

---

September 28, 2018

**Notification of application for manufacturing and marketing approval  
of HP-3000 (Transdermal, Parkinson's disease treatment patch)  
in Japan**

Hisamitsu Pharmaceutical Co., Inc. (Head Office: Tosu city, Saga Prefecture, Japan; Chairman and CEO: Hirotaka Nakatomi, hereinafter referred to as "Hisamitsu Pharmaceutical") announced today that it has submitted a new drug application for the Parkinson's disease treatment patch (Development code: HP-3000, generic name: ropinirole hydrochloride, hereinafter referred to as "the product").

The product is a systemic transdermal Parkinson's disease treatment patch developed by Hisamitsu's TDDS (Transdermal Drug Delivery System) technologies. Hisamitsu Pharmaceutical expects its long-lasting effect by means of maintaining a stable blood concentration, and the product to be a new option for treating Parkinson's disease.

Hisamitsu Pharmaceutical will contribute improvement of Quality of Life of the patients with Parkinson's disease through the product.

Hisamitsu aims to obtain a manufacturing and marketing approval during FY2019.